

**NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE**

**Multiple Health Technology Appraisal (MTA)**

**Omalizumab for the treatment of severe persistent allergic asthma (review of TA133 and TA201)**

**Response to consultee and commentator comments on the provisional matrix of consultees and commentators**

<b>Version of matrix of consultees and commentators reviewed:</b>					
Provisional matrix of consultees and commentators sent for consultation					
<b>Summary of comments, action taken, and justification of action:</b>					
	<i>Proposal:</i>	<i>Proposal made by:</i>		<i>Action taken:</i> Removed/Added/Not included/Noted	<i>Justification:</i>
	Recommend that the Severe Asthma National Network (SANN) is also included under the heading of Professional Groups. The Chair of the group is Beverley Hargadon (Glenfield Respiratory Unit, UHL NHS Trust, Leicester) Co chaired by Mel McFeeters (Leicester Royal Infirmary)	Royal College of Nursing		Not included	We are unable to find any details about this group.

	<p>This [the matrix] should include:</p> <ul style="list-style-type: none"> <li>• The Anaphylaxis Campaign</li> <li>• Medical Research Council / Asthma UK funded centre for Asthma and Allergy jointly held by Imperial College and Kings College, London – current director Prof. Sebastian Johnston at Imperial</li> </ul>	<p>The Royal College of Paediatric and Child Health</p>	<p>Added</p>	<p>These groups meet the inclusion criteria and have been added to the matrix of consultees and commentators for this appraisal.</p>
--	---	---	--------------	--